Optimised prosthetic heart valve surfaces to prevent infective endocarditis.

Rogers, B. (Primary Chief Investigator (PCI)), Robson, C. (Chief Investigator (CI)), Qu, Y. (Chief Investigator (CI)), Peleg, A. (Chief Investigator (CI)), Bennetts, J. (Chief Investigator (CI)), Nicholls, S. (Chief Investigator (CI)) & Forsythe, J. (Chief Investigator (CI))

1/02/25 → 31/01/27

Project: Research

An Interventional Efficacy and Safety Phase 3, Double-Blind, 2-Arm Study to Investigate IV Followed by Oral Fosmanogepix Compared with IV Caspofungin Followed by Oral Fluconazole in Adult Participants with Candidemia and/or Invasive Candidiasis

Rogers, B. (Primary Chief Investigator (PCI))

21/10/24 → 20/10/29

Project: Research

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with Olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species

Rogers, B. (Primary Chief Investigator (PCI))

21/08/24 → 20/08/29

Project: Research

Optimised Outpatient Parenteral Antimicrobial Therapy

Rogers, B. (Primary Chief Investigator (PCI))

NHMRC - National Health and Medical Research Council (Australia)

1/01/23 → 31/12/27

Project: Research

Phase 1b/2a, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SAO2 as an Adjunct to Best Available Antibiotic Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus.

Rogers, B. (Primary Chief Investigator (PCI))

1/09/22 → 31/08/27

Project: Research